Goldman Sachs Group Inc. lowered its position in STERIS PLC (NYSE:STE) by 10.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 576,928 shares of the medical equipment provider’s stock after selling 68,315 shares during the quarter. Goldman Sachs Group Inc. owned about 0.68% of STERIS PLC worth $47,020,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. First Trust Advisors LP lifted its position in STERIS PLC by 14.0% in the 1st quarter. First Trust Advisors LP now owns 8,593 shares of the medical equipment provider’s stock worth $597,000 after buying an additional 1,055 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in STERIS PLC by 18.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 23,513 shares of the medical equipment provider’s stock worth $1,633,000 after buying an additional 3,683 shares during the last quarter. JPMorgan Chase & Co. lifted its position in STERIS PLC by 2.3% in the 1st quarter. JPMorgan Chase & Co. now owns 67,052 shares of the medical equipment provider’s stock worth $4,657,000 after buying an additional 1,490 shares during the last quarter. SG Americas Securities LLC bought a new stake in STERIS PLC in the 1st quarter worth approximately $1,098,000. Finally, Neuberger Berman Group LLC lifted its position in STERIS PLC by 71.3% in the 1st quarter. Neuberger Berman Group LLC now owns 7,635 shares of the medical equipment provider’s stock worth $530,000 after buying an additional 3,179 shares during the last quarter. 93.33% of the stock is owned by institutional investors and hedge funds.
STERIS PLC (STE) traded up 0.01% on Tuesday, hitting $90.68. The stock had a trading volume of 8,815 shares. The company has a 50 day moving average price of $87.82 and a 200-day moving average price of $80.92. STERIS PLC has a 52-week low of $63.80 and a 52-week high of $91.18. The company has a market cap of $7.73 billion, a price-to-earnings ratio of 64.86 and a beta of 1.29.
STERIS PLC (NYSE:STE) last issued its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.80 by $0.05. The firm had revenue of $608.00 million for the quarter, compared to analyst estimates of $597.66 million. STERIS PLC had a net margin of 4.63% and a return on equity of 11.39%. The firm’s revenue was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.79 EPS. On average, equities research analysts predict that STERIS PLC will post $4.06 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Tuesday, August 29th were paid a $0.31 dividend. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.37%. The ex-dividend date of this dividend was Friday, August 25th. This is a positive change from STERIS PLC’s previous quarterly dividend of $0.28. STERIS PLC’s dividend payout ratio is 88.57%.
In related news, Director Mohsen Sohi sold 2,744 shares of the stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $85.98, for a total transaction of $235,929.12. Following the sale, the director now owns 21,816 shares in the company, valued at $1,875,739.68. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the company’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $85.69, for a total transaction of $856,900.00. Following the completion of the transaction, the chief executive officer now owns 83,270 shares of the company’s stock, valued at approximately $7,135,406.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 194,086 shares of company stock worth $16,953,621. Company insiders own 2.55% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “STERIS PLC (STE) Shares Sold by Goldman Sachs Group Inc.” was originally published by BBNS and is owned by of BBNS. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://baseballnewssource.com/markets/goldman-sachs-group-inc-reduces-holdings-in-steris-plc-ste/1698877.html.
STE has been the subject of a number of recent analyst reports. Raymond James Financial, Inc. upped their target price on STERIS PLC from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Monday. Zacks Investment Research upgraded STERIS PLC from a “hold” rating to a “buy” rating and set a $92.00 target price for the company in a report on Tuesday, July 11th. Finally, BidaskClub cut STERIS PLC from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $90.25.
STERIS PLC Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for STERIS PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS PLC and related companies with our FREE daily email newsletter.